Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01529424 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT01529424 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 89 participants.
The verdict
NCT01529424, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the dose/response pharmacodynamic effects of ISIS ApoC-III Rx vs. Placebo on fasting total apoC-III levels.
Interventions
- DRUG Placebo
- DRUG ISIS apoC-III Rx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01529424
The ClinicalTrials.gov registry entry for NCT01529424 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01529424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01529424 about?
NCT01529424 is a clinical study titled "Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia". The purpose of this study is to evaluate the dose/response pharmacodynamic effects of ISIS ApoC-III Rx vs. Placebo on fasting total apoC-III levels.
What is the current status of trial NCT01529424?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2012-02. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01529424?
The interventions under investigation include: Placebo (DRUG), ISIS apoC-III Rx (DRUG).
Who is sponsoring clinical trial NCT01529424?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.